Inflacod Spółka z Ograniczoną Odpowiedzialnością (KRS 0000840765, NIP 9721308193) is a Polish company, headquartered in Złotniki, Wielkopolskie voivodeship. Inflacod operates in: Other research and experimental development on natural sciences and engineering (PKD 72.19.Z). Industry: Research and development. The company has been listed in the National Court Register since May 8, 2020.
No arrears identified in the analysed sources
No arrears or bankruptcy proceedings identified in the analysed sources.
Business profile - Inflacod
Identity
- Name
- Inflacod Spółka z Ograniczoną Odpowiedzialnością
- Legal form
- SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
- Founded
- May 8, 2020
- Registry status as of
- May 26, 2026
- Latest entry
- May 26, 2026
- Founding act
- 06.05.2020 R.
Articles of association history (2)
- May 6, 2020: 06.05.2020 R.
- AKT NOTARIALNY Z DNIA 15 MAJA 2020 R., REP. A NR 1506/2020, ZASTĘPCA NOTARIALNY PIOTR CIENIUCH Z KANCELARII NOTARIALNEJ MAGDALENY WALTER W POZNANIU, UL. NIECAŁA 12/3. UCHYLONO DOTYCHCZASOWĄ TREŚĆ UMOWY SPÓŁKI I NADANO JEJ W CAŁOŚCI NOWE BRZMIENIE. (PARAGRAFY OD 1 DO 17).
Activities
General codes (divisions and groups)
General codes indicate a PKD division or group without a specific subclass.
Address and contact
- Address
- UL. KRZEMOWA, 1, 62-002, ZŁOTNIKI, POLSKA
- Voivodeship
- WIELKOPOLSKIE
- District
- POZNAŃSKI
- Not disclosed in the registry
- Website
- Not disclosed in the registry
- E-delivery address
- AE:PL-72242-97519-VJBFR-30
Risk and payment profile - Inflacod
Credibility rating
56 / 100
Average credibility
Insolvency risk
Low
Elevated threat
Closure risk
25
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
Organisational stability signals
No instability signals - ownership, management, PKD codes and company name remain relatively stable.
Shareholder changes
1
1/6 yrs
Board changes
0
0/6 yrs
PKD changes
1
1/6 yrs
Name changes
0
0/6 yrs
Data from 6 years of registry activity.
Credibility history
Payment reliability score from 2020–2024
Current: C (56/100)
Trend: deteriorating (-4.6 pts/year)
Moderate payment credibility - the company is able to meet its obligations, but some indicators warrant caution.
Trade credit limit history
Standard limit from 2020–2024
Current: 201.4 K PLN
Safe: 90.6 K PLN
Difference between risk models
Closure - probability of ceasing operations (operational continuity). Insolvency - probability of formal bankruptcy / restructuring. The models use different data - results can diverge significantly when balance-sheet data is incomplete.
Operational status - Inflacod
Founded
May 8, 2020
6 years in operation
Legal form
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Registry: RejP
Headquarters
ZŁOTNIKI
WIELKOPOLSKIE
Primary PKD
72.19.Z
Other research and experimental development on natural sciences and…
Share capital
8.2 K PLN
163 shares total
Shareholders
2
shareholders
Board
1 person
Filed years
5 years
2020–2024 · profitable: 0/5
Registry entries
23
latest: May 26, 2026
Risk signals
Revenue
N/A
2024
Net profit
-3.4 K PLN
2024
Assets
1.0 M PLN
2024
Equity
200.5 K PLN
2024
EBITDA
N/A
2024
no depreciation data
Valuation
695.4 K PLN
Low confidence
Low confidence
Companies in the same location
Public procurement
Trademarks
Reviews
Rate business credibility - Inflacod.
No ratings
Related articles
News
Bioceltix in the final EMA dialogue phase: BCX-CM-J could become Europe's first veterinary cell-therapy drug for dogs
Wrocław-based Bioceltix S.A. (KRS 0000744521) entered Q2 2026 in the final EMA dialogue phase on BCX-CM-J – potentially Europe's first veterinary cell-therapy drug based on mesenchymal stem cells, for dogs with osteoarthritis. Responses to the EMA's final questions are due in May 2026; a CVMP recommendation and marketing authorisation are possible in Q3/Q4 2026. A pre-commercial biotech: it closed 2024 with a PLN 14.9m loss on zero revenue and PLN 33.6m of cash at year-end. Trigon DM maintains a buy rating with a PLN 127.2 price target.
News
Captor Therapeutics: PLN 36m of cash at 30 September 2025, runway to mid-2026 – clinical data versus the cash clock
Wrocław-based Captor Therapeutics S.A. (KRS 0000756383) – a pre-commercial biotech specialising in targeted protein degradation (TPD) – closed Q3 2025 with PLN 36m of cash and grants securing funding to mid-2026. CT-01 (hepatocellular carcinoma) entered Phase I, with the first patient dosed at the Barcelona Clinic Liver Cancer. CT-03, an MCL-1 degrader, is close to clinical entry. Without a new R&D partnership or share issue in 2026, the company will need additional financing.
